Long-Term Management of Generalised Anxiety Disorder with Low-Dose Continuous Infusions of Flumazenil: A Case Series.
GABA
anxiety disorder
flumazenil
infusion
remission
treatment response
Journal
Behavioral sciences (Basel, Switzerland)
ISSN: 2076-328X
Titre abrégé: Behav Sci (Basel)
Pays: Switzerland
ID NLM: 101576826
Informations de publication
Date de publication:
02 Nov 2022
02 Nov 2022
Historique:
received:
30
09
2022
revised:
28
10
2022
accepted:
30
10
2022
entrez:
10
11
2022
pubmed:
11
11
2022
medline:
11
11
2022
Statut:
epublish
Résumé
Generalised anxiety disorder (GAD) is a common anxiety disorder associated with social and occupational impairment. Recently, a theory was postulated that dysfunctional gamma aminobutyric acid type A receptors (GABA Participants had a primary diagnosis of GAD and were treated initially with an eight-day continuous low-dose flumazenil infusion (total 32 mg at a rate of 4 mg/24 h). Some participants were re-treated with a further four- or eight-day infusion. Treatment response was measured as a 50% reduction in anxiety or stress scores on the Depression Anxiety Stress Scale-21 (DASS-21). Remission was measured as scores ≤3 or ≤7 on the anxiety and stress subscales of the DASS-21, respectively. Eight cases are reported. All cases met the criteria for treatment response on the anxiety and stress subscale of the DASS-21. Remission was achieved in seven participants on the anxiety subscale and in five on the stress subscale. No changes in hepatic, renal, or haematological function were likely attributed to flumazenil. Data suggest that low-dose continuous flumazenil infusion manages GAD symptoms and is safe. Although these results are promising, future randomised control trials are required to confirm these results.
Sections du résumé
BACKGROUND
BACKGROUND
Generalised anxiety disorder (GAD) is a common anxiety disorder associated with social and occupational impairment. Recently, a theory was postulated that dysfunctional gamma aminobutyric acid type A receptors (GABA
METHOD
METHODS
Participants had a primary diagnosis of GAD and were treated initially with an eight-day continuous low-dose flumazenil infusion (total 32 mg at a rate of 4 mg/24 h). Some participants were re-treated with a further four- or eight-day infusion. Treatment response was measured as a 50% reduction in anxiety or stress scores on the Depression Anxiety Stress Scale-21 (DASS-21). Remission was measured as scores ≤3 or ≤7 on the anxiety and stress subscales of the DASS-21, respectively.
RESULTS
RESULTS
Eight cases are reported. All cases met the criteria for treatment response on the anxiety and stress subscale of the DASS-21. Remission was achieved in seven participants on the anxiety subscale and in five on the stress subscale. No changes in hepatic, renal, or haematological function were likely attributed to flumazenil.
CONCLUSION
CONCLUSIONS
Data suggest that low-dose continuous flumazenil infusion manages GAD symptoms and is safe. Although these results are promising, future randomised control trials are required to confirm these results.
Identifiants
pubmed: 36354407
pii: bs12110430
doi: 10.3390/bs12110430
pmc: PMC9687673
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Neurosci. 2007 Apr;10(4):469-77
pubmed: 17351635
Drug Alcohol Depend. 2022 Jul 1;236:109501
pubmed: 35644071
Brain Res Bull. 2016 Jan;120:131-43
pubmed: 26592470
Br J Pharmacol. 1997 Apr;120(8):1582-8
pubmed: 9113382
Clin Pharmacokinet. 1988 Jan;14(1):1-12
pubmed: 3127102
J Psychopharmacol. 2013 Feb;27(2):222-7
pubmed: 22596209
Ther Adv Psychopharmacol. 2022 Jun 30;12:20451253221105128
pubmed: 35795687
Neuropsychiatr Dis Treat. 2015 May 05;11:1149-55
pubmed: 25999720
Br J Clin Psychol. 1992 Sep;31(3):301-6
pubmed: 1393159
J Clin Psychiatry. 2009;70 Suppl 2:4-9
pubmed: 19371500
Neuropsychiatr Dis Treat. 2015 Jan 17;11:165-75
pubmed: 25653526
J Clin Psychiatry. 2014 Apr;75(4):362-8
pubmed: 24569045
J Psychopharmacol. 2017 Oct;31(10):1369-1373
pubmed: 28613124
Addict Biol. 2002 Oct;7(4):385-95
pubmed: 14578014
Behav Res Ther. 1997 Jan;35(1):79-89
pubmed: 9009048
J Psychopharmacol. 2014 Jul;28(7):703-6
pubmed: 24554692
Neuropharmacology. 2012 Dec;63(8):1315-26
pubmed: 22939998
Eur J Neurosci. 1998 Sep;10(9):2924-33
pubmed: 9758162
Neuropharmacology. 2002 Sep;43(4):701-14
pubmed: 12367616
J Clin Med. 2022 Oct 08;11(19):
pubmed: 36233814
Depress Anxiety. 2003;17(3):173-9
pubmed: 12768651
Psychopharmacology (Berl). 2014 Sep;231(17):3525-35
pubmed: 24740493
Psychiatry Res. 2020 Sep;291:113275
pubmed: 32763538
Stress. 2005 Jun;8(2):85-93
pubmed: 16019600
Neuroscience. 2013 Dec 19;254:452-75
pubmed: 23994152
J Clin Epidemiol. 1988;41(4):313-21
pubmed: 3351539
World J Biol Psychiatry. 2018;19(sup1):S36-S45
pubmed: 30204559
Anxiety Stress Coping. 2007 Sep;20(3):253-65
pubmed: 17999228
Clin Psychopharmacol Neurosci. 2020 Aug 31;18(3):423-433
pubmed: 32702221
Brain Res. 2012 Jun 29;1463:1-20
pubmed: 22609410
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2849-54
pubmed: 11226329
J Psychopharmacol. 2022 Apr;36(4):439-448
pubmed: 35475379
Nat Rev Drug Discov. 2010 Aug;9(8):628-42
pubmed: 20577266
Mol Psychiatry. 2006 Sep;11(9):805-14
pubmed: 16847460
Brain Res. 2001 Aug 10;910(1-2):55-66
pubmed: 11489254
J Neurochem. 2000 Aug;75(2):732-40
pubmed: 10899949